Clinical Trial Update: Tolvaptan Extension Study in Participants With ADPKD [Phase 3]

View source ↗

Summary

Phase 3 extension study update for Tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Status: COMPLETED | Results posted: 2021-10-25